南新制药(688189) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,624,818.43, a decrease of 70.21% compared to ¥111,835,236.68 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,028,308.26, representing a decline of 143.66% from a profit of ¥3,766,508.55 in the previous year[4] - The basic and diluted earnings per share were both -¥0.0293, down 143.73% from ¥0.0137 in the same period last year[5] - Net loss for Q1 2025 was ¥8,101,509.23, compared to a net profit of ¥21,423,835.82 in Q1 2024, indicating a significant decline in profitability[22] - Total operating revenue for Q1 2025 was ¥40,624,818.43, a decrease of 70.2% compared to ¥136,374,970.14 in Q1 2024[20] Research and Development - The total R&D investment amounted to ¥24,882,149.56, an increase of 50.68% compared to ¥16,512,853.64 in the previous year[5] - R&D investment accounted for 61.25% of operating revenue, an increase of 49.14 percentage points from 14.77% in the previous year[5] - Research and development expenses for Q1 2025 were ¥10,420,828.81, up 53.5% from ¥6,826,875.34 in Q1 2024, reflecting increased investment in innovation[20] Cash Flow and Liquidity - The net cash flow from operating activities was ¥99,338,104.85, an increase of 169.48% compared to ¥36,863,557.07 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was ¥99,338,104.85, an increase from ¥36,863,557.07 in Q1 2024[24] - Cash inflow from operating activities totaled ¥137,643,739.54 in Q1 2025, compared to ¥129,273,393.29 in Q1 2024, indicating improved cash generation[24] - The company's cash and cash equivalents increased to ¥550,365,903.94 from ¥490,270,275.37, representing an increase of approximately 12.0%[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,212,138,325.93, a decrease of 0.84% from ¥1,222,438,490.23 at the end of the previous year[5] - The equity attributable to shareholders was ¥928,563,813.61, down 0.86% from ¥936,592,121.87 at the end of the previous year[5] - Total liabilities as of the reporting date were ¥341,933,959.48, slightly down from ¥344,132,614.55 in the previous period[20] - The company’s total liabilities increased to ¥1,212,138,325.93, reflecting a stable financial position[16] Market Conditions - The decline in revenue and profit was primarily due to lower market demand for antiviral products and price reductions in response to market competition[8] - The company identified a need to adjust revenue recognition for certain products, resulting in a reduction of ¥24,539,700 in 2023 revenue and an increase in Q1 2024 revenue by the same amount[5] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,843[11] - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, accounting for 28.57% of total shares[12] - The number of shares held in the company's repurchase account is 1,570,586, accounting for 0.57% of the total share capital of 274,400,000 shares[12] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[13] Financial Reporting - The company did not apply new accounting standards starting from 2025[25] - The company’s financial reporting is overseen by Zhang Shixi, Li Liang, and Chen Xiaoning[26]